cdx-301
Recombinant proteinexperimental
Clinical trial activity
14 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1998 (NCT00019396)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Hodgkin Disease · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Prostatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stem Cells · Phase 2
- Stomach Neoplasms · Phase 1
- Tissues · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
Tyrosine-protein kinase receptor FLT3 agonist
- Fms-related tyrosine kinase 3 ligandANTAGONIST
FLT3LG antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650387 ↗
Also known as
- cdx-301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05029999 | Phase 1 | Dec 31, 2021 | Celldex Therapeutics, Gateway for Cancer Research, The University of Texas, Dallas |
| NCT04930783 | Phase 1 | Nov 30, 2021 | Celldex Therapeutics, Harvard University |
| NCT05010200 | Phase 1 | Sep 30, 2021 | Icahn School of Medicine at Mount Sinai |
| NCT04536077 | Phase 2 | Jan 31, 2021 | Celldex Therapeutics, Washington University in St. Louis |
| NCT04491084 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2021 | Celldex Therapeutics, Yeshiva University |
| NCT04616248 | Phase 1 | Dec 1, 2020 | State University of New York, Buffalo |
| NCT03804944 | Phase 2 | Sep 30, 2019 | Cornell University |
| NCT03835533 | Phase 1 | Jun 30, 2019 | Bristol-Myers Squibb, Cancer Research Institute, Celldex Therapeutics, Inovio Pharmaceuticals, Oncovir, Inc., The Parker Institute |
| NCT03789097 | Phase 1/Phase 2 (Phase 2) | Apr 5, 2019 | Celldex Therapeutics, Icahn School of Medicine at Mount Sinai, Merck |
| NCT03329950 | Phase 1 | Dec 1, 2017 | Celldex Therapeutics |
| NCT02839265 | Phase 2 | Jul 1, 2016 | Celldex Therapeutics, Yeshiva University |
| NCT02200380 | Phase 2 | Jul 1, 2014 | Celldex Therapeutics |
| NCT01465139 | Phase 1 | Oct 1, 2011 | Celldex Therapeutics |
| NCT00019396 | Phase 2 | Feb 1, 1998 | National Cancer Institute (NCI) |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 10 | 3 | 2 | 2011 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Yeshiva University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Gateway for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1998 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2019 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2020 |
| The Parker Institute | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
16 organizations
Page 1 / 1